President Biden has made drug pricing reform one of his signature initiatives and three years into his term, a number of significant programs are being implemented, mostly under the auspices of the Inflation Reduction Act of 2022. Drug pricing reform policies enacted and in the process of implementation, policies proposed and not yet implemented and industry efforts to stop one of the most impactful of the policies – Medicare price negotiation – are displayed below.
The Biden Administration And Biopharma: It’s Been A Tough Three Years
A round up of reform policies targeting the biopharma industry and its pricing practices that have been implemented or proposed by the Biden Administration to date.
More from Market Access
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
• By
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
• By
A former CMS manager worries casework and other necessary functions could suffer as a result of the 300 staff cuts at the agency that are part of a massive HHS restructuring.
More from Pink Sheet
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
• By
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
• By
In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."